Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach (DEEP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02393885|
Recruitment Status : Active, not recruiting
First Posted : March 20, 2015
Last Update Posted : May 25, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Persistent or Longstanding Persistent Atrial Fibrillation||Device: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||220 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach for Treatment of Subjects With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation|
|Actual Study Start Date :||February 2015|
|Estimated Primary Completion Date :||November 2024|
|Estimated Study Completion Date :||December 2027|
Experimental: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System
AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
Device: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation
Other Name: Irrigated Endocardial Catheters
- Freedom from any documented AF, atrial flutter, or atrial tachycardia lasting >30 seconds in duration through the 12 month follow-up visit in the absence of Class I or III AADs (with the exception of previously failed [ Time Frame: 6 months post the Endocaridal Ablation Procedure through the 12 month follow-up visit ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
1. Symptomatic Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation refractory to a minimum of one Class I or Class III AADs.
- AF >10 years.
- Refractory hypertension, defined as systolic (>150 mm Hg) or diastolic (> 90 mm Hg) blood pressure that remains uncontrolled despite sustained therapy
- History of pulmonary hypertension
- Pulmonary vein stenosis in one or more of the pulmonary veins
- EP catheter ablation procedure to treat atrial fibrillation within 3 months
- Undergone prior cardiothoracic surgery, previous thorax trauma which resulted in a pneumothorax or hemothorax.
- Sleep apnea, home oxygen therapy, moderate to severe COPD, (FEV1/FVC < 70% predicted) or patient is considered intolerant to single lung ventilation.
- NYHA Class IV heart failure.
- Uncorrected, reversible cause(s) of atrial fibrillation, or is currently being treated for arrhythmias other than atrial fibrillation (AF) or atrial flutter.
- Documented history of previous catheter ablation with perforation, history of pericarditis, pericardial effusion, or tamponade.
- Structural heart disease requiring surgical treatment (i.e. valve disease requiring repair or replacement within 12 months following surgical ablation procedure).
- CAD requiring intervention (either surgical, i.e. CABG, or catheter).
- Ejection fraction < 30%
- Measured left atrial diameter > 5.5 cm
- Stroke/cerebrovascular accident (CVA) within previous six months, carotid artery stenosis greater than 80%.
- BMI is >40
- Thrombus in the left atrium or the left atrial appendage, determined by echocardiography (either at baseline TTE (or equivalent diagnostic test) or intraoperative TEE).
- Blood dyscrasia or clotting disorder (i.e. Idiopathic Thrombocytopenic Purpura [ITP] or Thrombotic Thrombocytopenic Purpura [TTP]).
- Contraindication to anticoagulation that in the opinion of the investigator poses undue risk to the patient from participating in the endocardial EP procedure.
- Documented thromboembolism within the previous six months prior to signing informed consent.
- Has the following atrial myxoma, mural thrombus or mural tumor.
- A condition or congenital anomaly which prevents required surgical or catheter access.
- A co-morbid condition that, in the opinion of the investigator, poses undue risk of general anesthesia or port access cardiac surgery.
- Currently abusing drugs or alcohol.
- Currently or has participated in a clinical study in the last 3 months prior to signing informed consent.
- A psychological disorder that could interfere with provision of informed consent, completion of tests, therapy, or follow-up.
- A condition that, in the opinion of the investigator, may jeopardize the patient's well-being and/or the soundness of this clinical study.
- Pre-existing esophageal condition that required (or requires) endoscopic therapy or surgical treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02393885
|Principal Investigator:||Kenneth Ellenbogen, MD||VCU|
|Principal Investigator:||Vigneshwar Kasirajan, MD||VCU|
|Principal Investigator:||Ali Khoynezhad, MD||MemorialCare Long Beach Medical Ctr|
|Responsible Party:||AtriCure, Inc.|
|Other Study ID Numbers:||
|First Posted:||March 20, 2015 Key Record Dates|
|Last Update Posted:||May 25, 2022|
|Last Verified:||October 2021|
|Studies a U.S. FDA-regulated Device Product:||Yes|